A Randomized, Single-blind, Placebo-control, Parallel, Phase II Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection
Latest Information Update: 06 Oct 2022
Price :
$35 *
At a glance
- Drugs UB 621 (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors UBP Greater China (Shanghai) Co., Ltd
- 29 Sep 2022 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 29 Sep 2022 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 29 Sep 2022 Planned initiation date changed from 1 Dec 2022 to 1 Dec 2023.